Becton, Dickinson and Company

BDX • Medical - Instruments & Supplies

$184.74

▼ -2.88 (-1.54%)

Precio actual

ResultadosÚltimo reporte: 30 jun 2026

PERFIL EQUILIBRADONeutralConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Perfil mixto. La empresa no es necesariamente mala, pero la valoración, el crecimiento o el balance todavía no justifican una señal más fuerte.

Capitalización

$52.02B

Crecimiento

8.0%

Flujo de caja

5/5

Tendencia

Stable

Evidencia

Flujo de caja libre positivo · 9.32Flujo de caja libre consistente · 5/5Nivel de deuda manejable · 0.76Tendencia de crecimiento negativa

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 7 ago 2026, 12:16 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$184.74

Change-1.54%

Shares Out281.60M

Market Cap$52.02B

Enterprise Value$65.83B

52W Range127.59 - 187.35

Beta0.27

P/E55.23

P/S2.59

P/B1.03

P/FCF19.06

EV/Sales3.28

Price$184.74

Change-1.54%

Shares Out281.60M

Market Cap$52.02B

Enterprise Value$65.83B

52W Range127.59 - 187.35

Beta0.27

P/E55.23

P/S2.59

P/B1.03

P/FCF19.06

EV/Sales3.28

EV/EBITDA52.96

EV/FCF24.11

Earnings Yield1.81%

FCF Yield5.25%

Dividend Yield1.69%

Gross Margin45.44%

Oper. Margin11.80%

Profit Margin7.68%

Debt/Eq0.76

Current Ratio1.11

Quick Ratio0.64

Revenue 5Y8.00%

Target$186.88

Target Upside1.16%

Target Median$190.00

Target Range159.00 - 210.00

Volume3.29M

Avg Volume2.73M

EPS Surprise0.12

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

57/100

Fortaleza financiera

Deuda, caja, estabilidad

50/100

Potencial de crecimiento

Ingresos y expansión

38/100

Atractivo del precio

Barata o cara hoy

76/100

Por qué este puntaje▼

Flujo de caja libre positivo · 9.32Flujo de caja libre consistente · 5/5Nivel de deuda manejable · 0.76Tendencia de crecimiento negativa

Analyst view

Analyst sentiment and price target

BDX

Analyst sentiment

Based on 34 analyst votes · 2026-09-05

72/100

Bullish

Hold

Bearish

Precio objetivo

2026-08-07

Bajo

$159.00

Promedio

$183.57

Mediana

$180.00

Alto

$210.00

Resumen de la compañía

IPO: 2/21/1973

Industria: Medical - Instruments & Supplies

P/B i: 1.03

Deuda / Patrimonio i: 0.76

Margen operativo: 11.80%

Margen neto: 7.68%

ROE i: -

ROIC: -

Salud financiera

Puntaje10 / 20

Deuda / Patrimonio: 0.76

Ratio corriente: 1.11

Ratio rápido: 0.64

Estado: Moderate

Advertencias

Weak quick ratio

Transacciones internas

Actividad reciente de ejecutivos e insiders

Byington Carrie L

Transacción: 08/06/2026

COMPRA

Cambio

+94

Precio

Not reported

Presentación

08/06/2026

Tipo

COMPRA

Huffines Robert Luther

Transacción: 08/06/2026

COMPRA

Cambio

+189

Precio

Not reported

Presentación

08/06/2026

Tipo

COMPRA

Feld Michael

Transacción: 07/27/2026

VENTA

Cambio

-75

Precio

$157.13

Presentación

07/28/2026

Tipo

VENTA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Byington Carrie L	COMPRA	+94	Not reported	08/06/2026	08/06/2026
Huffines Robert Luther	COMPRA	+189	Not reported	08/06/2026	08/06/2026
Feld Michael	VENTA	-75	$157.13	07/27/2026	07/28/2026
Muhsin Bilal	VENTA	-1,935	Not reported	07/02/2026	07/06/2026
Muhsin Bilal	COMPRA	+14,342	Not reported	07/01/2026	07/06/2026
Feld Michael	VENTA	-75	$152.80	06/26/2026	06/26/2026
Garrison Michael David	VENTA	-1,100	$145.66	06/24/2026	06/25/2026
Sinha Manish	OTRO	0	Not reported	06/22/2026	06/22/2026
Sinha Manish	OTRO	+2,663	$168.49	11/26/2025	06/22/2026
Sinha Manish	OTRO	+3,147	$179.49	11/26/2024	06/22/2026
Sinha Manish	OTRO	+3,408	$178.86	11/26/2023	06/22/2026
Sinha Manish	OTRO	+3,555	$181.15	11/26/2022	06/22/2026
Sinha Manish	OTRO	+5,690	$168.13	11/26/2021	06/22/2026
Sinha Manish	OTRO	+4,441	$188.63	11/26/2020	06/22/2026
Sinha Manish	OTRO	+4,100	$178.94	11/26/2019	06/22/2026
Sinha Manish	OTRO	+4,174	$167.25	11/26/2018	06/22/2026
Garrison Michael David	VENTA	-1,100	$151.48	06/10/2026	06/11/2026
Polen Thomas E Jr	VENTA	-20,209	$126.16	06/01/2026	06/03/2026
Polen Thomas E Jr	VENTA	-17,445	$146.15	06/01/2026	06/03/2026
Menziuso Peter	OTRO	0	Not reported	06/01/2026	06/02/2026

Sobre la compañía

Becton, Dickinson and Company

Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems. Additionally, this segment develops integrated systems for IV medication and infusion therapy, medication compounding workflow, automated dispensing, and supply chain optimization. Specialized products for diabetes management, including pen needles, along with prefillable drug delivery systems, are also key offerings. BD Life Sciences focuses on diagnostic and research tools, offering products for specimen and blood collection. This segment supplies automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification, and drug susceptibility analysis. It also provides liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media. Furthermore, it offers advanced solutions for cell analysis, including fluorescence-activated cell sorters and analyzers, antibodies, kits, and reagent systems. These are crucial for single-cell gene expression analysis, as well as for clinical oncology, immunological, and transplantation diagnostics and monitoring. Finally, the BD Interventional segment delivers specialized products for surgical and interventional procedures. Its portfolio includes solutions for hernia and soft tissue repair, biological and bioresorbable grafts, and biosurgery, alongside other surgical products. This segment also addresses surgical infection prevention, provides a range of surgical and laparoscopic instrumentation, offers peripheral intervention products, and supplies urology and critical care devices. Established in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.

Fuente - Link

Competidores

A ALC ARGX CAH EW HLN IDXX IQV RMD VEEV

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

BDX DCF Analysis: Intrinsic Value $157 vs Price $187

On September 02, 2026, we delve into the DCF analysis for Becton Dickinson and Co (BDX), a company that has shown notable price performance with a year-to-date in

GuruFocus

Two Recessions Couldn't Stop These 4 Healthcare Stocks From Raising Dividends

Two brutal recessions wiped out dividends across the market, yet a handful of healthcare companies kept raising their payouts through every quarter of both downturns.

24/7 Wall Street

Jim Cramer Calls This Mining Stock an Inflation Hedge “Just as Good as Crypto”

On a recent edition of CNBC's Mad Money Lightning Round, Jim Cramer fielded questions from viewers. Two of Cramer's clearest calls were to buy Vale (NYSE:VALE | VALE Price Prediction) as an inflation hedge comparable to cryptocurrency and to stay long Apple (NASDAQ:AAPL) through an upcoming leadership change.

24/7 Wall Street

BD Extends Leadership in Advanced Tissue Regeneration Through Continued Clinical Innovation

STANCE trial surpasses a key enrollment milestone, advancing the clinical evaluation of GalaFLEX LITE™ Scaffold and generating evidence to support its use in breast revision surgery for capsular contracture FRANKLIN LAKES, N.J., Aug. 27, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a significant milestone in its advanced tissue regeneration strategy and expansion efforts with the STANCE clinical trial evaluating GalaFLEX LITE™ Scaffold in breast revision surgery for capsular contracture.

PRNewsWire

BD to Present at Wells Fargo 21st Annual Healthcare Conference

FRANKLIN LAKES, N.J., Aug. 26, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 9:30 a.m.

PRNewsWire

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-07	2.78	2.9	0.12
2026-02-09	2.21	2.91	0.7
2025-11-06	3.92	3.96	0.04
2025-08-07	3.4	3.68	0.28
2025-05-01	3.28	3.35	0.07
2025-02-05	3	3.43	0.43
2024-11-07	3.77	3.81	0.04
2024-08-01	3.31	3.5	0.19
2024-05-02	2.97	3.17	0.2
2024-02-01	2.4	2.68	0.28
2023-11-09	3.42	3.42	0
2023-08-03	2.89	2.96	0.07